PTCT 250516 60.00C(PTCT250516C60000) Stock Price Today

US OptionsDetailed Quotes

PTCT250516C60000

Watchlist

1.70
-0.26-13.27%

15min DelayTrading Apr 30 09:43 ET

1.70High1.70Low

Intraday

5D
Daily

News

PTC and Schaeffler Expand Strategic Relationship With Adoption of Windchill+ PLM
PR NewswireApr 30 08:30 ET
Leerink Partners Maintains PTC Therapeutics(PTCT.US) With Hold Rating, Announces Target Price $52
Moomoo NewsApr 30 02:31 ET · Ratings
Express News | PTC Therapeutics Inc : Leerink Partners Raises Target Price to $52 From $50
ReutersApr 29 08:11 ET
William Blair Maintains PTC Therapeutics(PTCT.US) With Buy Rating
Moomoo NewsApr 26 04:33 ET · Ratings
PTC and Jazz Pharmaceuticals Among Latest Firms to Win EU Backing for Drugs
Seeking AlphaApr 25 12:29 ET
Positive Outlook for PTC Therapeutics: Buy Rating Affirmed Amid European and U.S. Approval Prospects for Sephience
TipRanksApr 25 11:45 ET · Ratings

Comments

Teddy123

Mar 20 20:26

PTC Therapeutics Presents New Sepiapterin Data from Ongoing Studies

$PTC Therapeutics (PTCT.US)$
Breakthrough PKU Treatment Enables 126% Higher Protein Intake in Clinical Trial

Teddy123

Feb 19 20:27

PTC Therapeutics Announces FDA Acceptance and Priority Review for Vatiquinone NDA for the Treatment of Children and Adults with Friedreich's Ataxia

$PTC Therapeutics (PTCT.US)$
Could This Rare Disease Drug Be PTC's Next Breakthrough? FDA Priority Review Reveals Major Potential

Lnova

Dec 20, 2024 07:24

$PTC Therapeutics (PTCT.US)$
PTC Therapeutics Announces Vatiquinone NDA Submission to FDA for the Treatment of Children and Adults Living with Friedreich Ataxia
12/19/2024 08:00AM ET
- If approved, vatiquinone would be the first and only authorized therapy for children with FA -
- PTC's fourth approval application submitted to FDA in 2024 -
WARREN, N.J., Dec. 19, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ:PTCT) announced today the submission of the vatiquinone New Drug Application (NDA) ...

Meltyy

May 22, 2024 15:52

Biotech Stock Catalyst Watchlist 👀

🎯 Ph 2 readouts in Q2 2024...
$Iovance Biotherapeutics (IOVA.US)$ Phase 2
$Supernus Pharmaceuticals (SUPN.US)$ Phase 2a
$BRANDES INTERNATIONAL ETF (BINV.US)$ Phase 2a
$MorphoSys (MOR.US)$ Phase 2
$Nuvation Bio (NUVB.US)$ Phase 2
$ALX Oncology (ALXO.US)$ Phase 2
$BioXcel Therapeutics (BTAI.US)$ Phase 2
$Purple Biotech (PPBT.US)$ Phase 2
$Arcus Biosciences (RCUS.US)$ Phase 2
$Medicenna Therapeutics (MDNAF.US)$ Phase 2b
$Affimed NV (AFMD.US)$ Phase 2
$Barinthus Biotherapeutics (BRNS.US)$ Phase 2b...

mad541

May 20, 2024 20:38

$PTC Therapeutics (PTCT.US)$ just dud offering 22.87 a share get out 🔻🔻🔻🔻